To evaluate long-term safety and efficacy of facilitated subcutaneous immunoglobulin (fSCIG; human immunoglobulin G [IgG] 10% with recombinant human hyaluronidase) in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
No takes yet. Share an insight, caveat, or question.
Hadden et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: